News & Updates
Inside Innovation
The latest news and advances from the world's most exciting life science cluster.
Is Money the Cure-All? Seattle-area biotech companies are striking deals, but questions loom about the market’s access to talent
Despite an economic downturn, investment in Seattle’s biotech industry hasn’t slowed down this year. With Athira Pharma’s September IPO that raised $204 million, life science
Phase Genomics lands $3.9M in grants to improve testing for chromosomal abnormalities
Seattle-based Phase Genomics announced that it received two National Institutes of Health (NIH) grants totaling $3.9 million over three years. The funding will go towards
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Sonoma Biosciences, which splits operations between South San Francisco and Seattle, received $40 million in financing to develop cell therapies for autoimmune diseases. Traditionally used
Seattle biotech Silverback Therapeutics raises $85M, just six months after raising $78.5M
Silverback Therapeutics announced that it received $85 million in Series C funding, following closely on the heels of a $78.5 million funding round in March
Merck, Seattle Genetics form partnerships worth $4.5B focused on two cancer drugs
Pharmaceutical company Merck and Bothell, Washington-based Seattle Genetics have formed a partnership to advance two key cancer therapies. The first involves expanding Tukysa, the drug
Gilead Moves Deeper into Oncology with $21 Billion Acquisition of Immunomedics
Gilead Sciences announced it has acquired Immunomedics, a developer of antibody-drug conjugate (ADC) technology used to treat cancers. Immunomedics gained attention with the success of